Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.verified

ARQT

Price:

$9.2

Market Cap:

$1.07B

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known...[Read more]

Industry

Biotechnology

IPO Date

2020-01-31

Stock Exchange

NASDAQ

Ticker

ARQT

The Current Ratio as of May 2024 (TTM) for Arcutis Biotherapeutics, Inc. (ARQT) is 9.89

According to Arcutis Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 9.89. This represents a change of 23.21% compared to the average of 8.03 of the last 4 quarters.

Arcutis Biotherapeutics, Inc. (ARQT) Historical Current Ratio (quarterly & annually)

How has ARQT Current Ratio performed in the past?

The mean historical Current Ratio of Arcutis Biotherapeutics, Inc. over the last ten years is 12.67. The current 9.89 Current Ratio has changed 7.71% with respect to the historical average. Over the past ten years (40 quarters), ARQT's Current Ratio was at its highest in in the June 2021 quarter at 32.03. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

Quarterly (TTM)
Annual

Average

12.67

Median

12.09

Minimum

5.52

Maximum

20.33

Arcutis Biotherapeutics, Inc. (ARQT) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Arcutis Biotherapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 246.39%

Maximum Annual Current Ratio = 20.33

Minimum Annual Increase = -38.80%

Minimum Annual Current Ratio = 5.52

Quarterly (TTM)
Annual
YearCurrent RatioChange
20237.08-38.80%
202211.57-4.27%
202112.09-6.71%
202012.96-36.28%
201920.336.35%
201819.12246.39%

Arcutis Biotherapeutics, Inc. (ARQT) Average Current Ratio

How has ARQT Current Ratio performed in the past?

The current Current Ratio of Arcutis Biotherapeutics, Inc. (ARQT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

10.25

5-year avg

12.80

10-year avg

12.67

Arcutis Biotherapeutics, Inc. (ARQT) Current Ratio vs. Peers

How is ARQT’s Current Ratio compared to its peers?

Arcutis Biotherapeutics, Inc.’s Current Ratio is less than Terns Pharmaceuticals, Inc. (27.85), greater than Amylyx Pharmaceuticals, Inc. (4.48), less than Acumen Pharmaceuticals, Inc. (30.20), less than Inozyme Pharma, Inc. (14.05), greater than X4 Pharmaceuticals, Inc. (3.71), less than Icosavax, Inc. (18.06), greater than Mirum Pharmaceuticals, Inc. (3.68), greater than VectivBio Holding AG (9.14), less than Day One Biopharmaceuticals, Inc. (10.93), greater than Mirati Therapeutics, Inc. (7.54), greater than Apellis Pharmaceuticals, Inc. (3.77), greater than Spero Therapeutics, Inc. (3.35), greater than Bolt Biotherapeutics, Inc. (5.68), greater than Coherus BioSciences, Inc. (1.17), greater than Gracell Biotechnologies Inc. (7.73), less than Neoleukin Therapeutics, Inc. (15.33), less than Theseus Pharmaceuticals, Inc. (29.93), greater than Monte Rosa Therapeutics, Inc. (4.82), less than Design Therapeutics, Inc. (38.61), less than Erasca, Inc. (10.14),

Build a custom stock screener for Arcutis Biotherapeutics, Inc. (ARQT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcutis Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Arcutis Biotherapeutics, Inc. (ARQT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Arcutis Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Current Ratio?

How can you use the Current Ratio?

What is Arcutis Biotherapeutics, Inc.'s Current Ratio?

How is the Current Ratio calculated for Arcutis Biotherapeutics, Inc. (ARQT)?

What is the highest Current Ratio for Arcutis Biotherapeutics, Inc. (ARQT)?

What is the 3-year average Current Ratio for Arcutis Biotherapeutics, Inc. (ARQT)?

What is the 5-year average Current Ratio for Arcutis Biotherapeutics, Inc. (ARQT)?

How does the current Current Ratio for Arcutis Biotherapeutics, Inc. (ARQT) compare to its historical average?